Changes in Beneficial Ownership · 4
AVADEL PHARMACEUTICALS PLC
Changes in Beneficial Ownership
Company context
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Avadel’s approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration as the first and only once-at-bedtime oxybate for extended-release oral suspension for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy. For more information, please visit Avadel’s website at www.avadel.com.
Historical securities (1)
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗